.-Studies to more clearly determine the mechanisms associated with arginine vasopressin (AVP)-induced vasodilation were performed in normal subjects and in quadriplegic subjects with impaired efferent sympathetic responses. Studies to compare the effects of AVP with the hemodynamic effects of nitroglycerin, an agent that primarily affects venous capacitance vessels, were also performed in normal subjects. Incremental infusions of AVP following V 1-receptor blockade resulted in equivalent reductions in systemic vascular resistance (SVRI) in normal and in quadriplegic subjects. However, there were major differences in the effect on mean arterial pressure (MAP), which was reduced in quadriplegic subjects but did not change in normal subjects. This difference in MAP can be attributed to a difference in the magnitude of increase in cardiac output (CI), which was twofold greater in normal than in quadriplegic subjects. These observations are consistent with AVP-induced vasodilation of arterial resistance vessels with reflex sympathetic enhancement of CI and are clearly different from the hemodynamic effects of nitroglycerin, i.e., reductions in MAP, CI, and indexes of cardiac preload, with only minor changes in SVRI.
IT IS NOW GENERALLY ACCEPTED that arginine vasopressin (AVP), a potent vasoconstrictor, is also capable of producing vasodilation. However, the mechanisms involved in the vasodilatory response to AVP are incompletely understood and may not be uniformly the same in all segments of the circulation. Although there is evidence that AVP-induced vasodilation may involve V 1 receptors in some highly localized vascular beds (16, 17) , a vasodilatory effect of AVP has been most clearly demonstrated following V 1 -receptor antagonist administration (13, 20, 27, 28) . In early studies reported by Schwartz and Reid (28) , V 1 -receptor antagonist administration in water-deprived conscious dogs was shown to produce hemodynamic changes that were the opposite of those usually associated with increased levels of AVP, i.e., cardiac output (CI), heart rate (HR), and plasma renin activity (PRA) were increased. In subsequent studies by Schwartz et al. (27) , it was shown that the hemodynamic changes produced by infusions of AVP after V 1 -receptor blockade in conscious dogs were similar to those produced by administration of a V 2 -receptor agonist VDAVP. Studies by Liard (21) in which the increase in CI associated with AVP infusion after V 1 -receptor blockade was prevented by prior administration of a combined V 1 ϩ V 2 -receptor antagonist and studies showing the absence of hemodynamic responses to dDAVP, a specific V 2 -receptor agonist, in patients with V 2 -deficient congenital diabetes insipidus (4) provided further evidence that extrarenal V 2 or V 2 -equivalent receptors may be involved in the vasodilatory response to AVP.
Vasopressin infusions after V 1 -receptor antagonist administration have been shown to produce marked reductions in mean arterial pressure (MAP) in quadriplegic subjects with deficient sympathetic efferent responses due to cervical spinal cord injury (13) . This effect on arterial pressure was attributed to unopposed AVP-induced vasodilation of arterial resistance vessels in quadriplegic subjects. We have extended our observations in these studies to include other hemodynamic parameters in both quadriplegic and normal subjects using thoracic electrical bioimpedance cardiography to more clearly identify the cardiovascular and circulatory effects of AVP after V 1 -receptor blockade with and without the interposition of sympathetic counterregulatory responses. In additional studies, the effects of AVP after V 1 -receptor blockade were compared with those of nitroglycerin, a precursor of nitric oxide with biological effects similar to those of endogenously generated nitric oxide (1, 2) . The purpose in this combination of studies is to provide a more comprehensive assessment of the hemodynamic effects of AVP-induced vasodilation after V 1 -receptor blockade and to differentiate these effects from those associated with administration of a vasodilating agent that primarily affects venous capacitance vessels.
METHODS
Study subjects. AVP infusion studies were performed in seven quadriplegic subjects with traumatic cervical spinal cord injury (C5-C7) that had been present for 3 mo to 10 yr and in five normal subjects. All subjects with spinal cord injury were accustomed to spending several hours daily in a wheelchair. There was no evidence of heart or liver disease or impairment of kidney function, as shown by serum creatinine concentrations, in any subject, and no one was receiving medications that are known to affect blood pressure, HR, or the hormonal parameters of interest. Quadriplegic subjects were allowed to continue their usual medications, which included multivitamins, vitamin C, acetaminophen, and benzodiazepine used to attenuate muscle spasms.
Five normal volunteer subjects, including three who also participated in the AVP infusion studies, received incremental infusions of nitroglycerin. The interval between the AVP and nitroglycerin infusion studies in these three subjects was 4-6 mo. None of the normal subjects in either study had been taking medications. All subjects had been eating their customary diet without NaCl or fluid restriction before the studies, and all avoided the use of tobacco and ethanol for at least 12 h before each study. Written informed consent was obtained from all participants, and the studies were approved by the Human Studies Subcommittee and the Research and Development Committee of the Veterans Affairs Medical Center.
Study protocol. All AVP infusion studies began at approximately 0800 after an overnight fast. On the morning of the studies, catheters were inserted into antecubital or forearm veins of both arms of supine subjects. After a 30-min period during which arterial blood pressure and HR were measured every 2 min using an arm cuff and an automated recording device (Dinamap, Critikon, Tampa, FL), blood samples were obtained for determinations of plasma norepinephrine (P NE) concentration, PRA, cGMP, and plasma atrial natriuretic peptide (PANP) concentrations. The V1-receptor antagonist, d(CH2)5Tyr (Me) AVP (0.5 mg in 0.9% NaCl), was then administered intravenously over 5 min. After an additional 45-min period of observation, at the peak effect of the V1-receptor antagonist, AVP (aqueous vasopressin, USP, 20 U/ml, American Reagent Laboratory, Shirley, NY) was infused at rates of 400, 800, 1,600, and 3,200 U ⅐ kg Ϫ1 ⅐ min Ϫ1 in 10-min consecutive intervals in all subjects. Observations were continued for 30 min after discontinuing the AVP infusion. The V1-receptor antagonist has been shown to be maximally effective within 45 min and to have a total duration of action exceeding 3 h (9). Bussien et al. (5) have shown that there is no effect of this antagonist on systolic or diastolic blood pressure when administered alone in studies performed over a period of 60 min in normally hydrated healthy subjects.
Arterial blood pressure and HR were measured every 2 min, and electrocardiographic monitoring was continuous throughout the studies. Blood samples were obtained immediately before the AVP infusions and at the end of each of the incremental infusion periods for measurements of PNE, PRA, cGMP, and P ANP. Measurements of plasma AVP (PAVP) could not be obtained in the presence of the V 1-receptor antagonist because of cross-reactivity with the antibody used in the radioimmunoassay for PAVP. The total volume of all blood samples in each study was ϳ150 ml. This volume was replaced with 0.9% NaCl after each collection of blood samples during the studies.
The median of the last 10 measurements of arterial blood pressure and HR before each collection of blood samples was selected as representative of that period. For postinfusion observations, measurements were obtained during the final 15 min of the 30-min postinfusion period. The MAP was calculated from the diastolic pressure plus (0.33 ϫ pulse pressure). AVP infusions were well tolerated in all subjects. There were no episodes of cardiac arrhythmia and no electrocardiographic changes or chest pain in any subject.
Cardiovascular parameters were assessed noninvasively by thoracic electrical bioimpedance cardiography (Bomed Medical Manufacturer, Irvine, CA). CI, stroke volume (SI), systemic vascular resistance (SVRI), end-diastolic index (EDI), which is a measure of preload, left cardiac work index (LCWI), ejection fraction (EF), and thoracic fluid conductivity (TFC) were continuously recorded (7, 11, 18, 30, 38) . TFC (1/ohm), the total conductivity of the thorax, is the reciprocal of the thoracic fluid index (Zo). Zo represents total impedance [resistance (ohm) to high-frequency alternating current] of the thorax. As more fluid is present within the thorax, the thorax becomes more conductive, and its Zo will be lower and TFC higher. Previous studies have shown a close correlation between measured right atrial pressure and TFC (7, 11) . In our laboratory, we have previously demonstrated decreasing TFC and EDI in both normal and quadriplegic subjects during incremental upright tilting, a condition that is known to decrease central blood volume (36) . All values were indexed by body surface area.
In the nitroglycerin infusion studies, nitroglycerin (200 g/ml in 5% dextrose, Abbott Laboratories, North Chicago, IL) was infused at rates of 25, 50, 75, 100, and 125 g ⅐ kg Ϫ1 ⅐ min Ϫ1 in 10-min consecutive intervals. Hemodynamic parameters were assessed noninvasively by thoracic electrical bioimpendance cardiography, and blood samples for measurements of hormonal parameters were obtained as in the AVP infusion studies.
Analytic methods. Blood for determinations of PNE, PRA, cGMP, and PANP was drawn into heparinized prechilled plastic syringes and placed in prechilled polypropylene tubes containing 10 mg EDTA/ml blood. Aprotinin (500 KIU) was added to the samples of blood used for determinations of PANP. Samples were kept in ice until centrifuged at 4 o C, and the separated plasma was stored at Ϫ20 o C until the analyses could be performed. PRA was measured by a modification of the radioimmunoassay method of Haber using antibody and reagents provided by Incstar (Stillwater, MN). PNE concentrations were determined by HPLC (National Reference Laboratory, Nashville, TN). PANP concentrations were measured by radioimmunoassay as previously described (13) . Plasma samples adjusted to pH 3.5 are loaded onto solid-phase extraction cartridges (Sep-Pak), eluted with 86% ethanol, dried, and reconstituted in assay buffer for the radioimmunoassay. Recovery of known quantities of PANP ϭ 86 Ϯ 2.7% (n ϭ 10). Intra-assay and interassay coefficients of variation are 8 and 10%, respectively. The lower limit of sensitivity for PANP in this assay is ϳ10 pg/ml. Plasma cyclic GMP was measured using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI).
Statistical analysis. Comparisons between groups (quadriplegic and normal subjects) before and during AVP infusions were made using a t-test for unpaired variates. The effect of AVP and nitroglycerin infusions in normal subjects was assessed using a one-factor ANOVA for repeated measures and Fisher's protected least-squares differences for within-group comparisons. In the analysis of data from the nitroglycerin infusion studies, values for missing data for infusion rates of 100 and 125 g ⅐ kg Ϫ1 ⅐ min Ϫ1 for one subject whose study was continued only through the 75 g ⅐ kg Ϫ1 ⅐ min Ϫ1 infusion were calculated using linear regression equations derived from preinfusion and 25-, 50-, and 75-g ⅐ kg Ϫ1 ⅐ min Ϫ1 infusion rate data. Correlation coefficients (R 2 ) ranged from 0.821 to 0.999 for all variables except EF, TFC, PRA, cGMP, and PANP. Data for these variables for all infusion rates were analyzed separately with n ϭ 4 (subjects with no missing data). Plasma samples for determinations of P NE were not collected at the lower infusion rates in the nitroglycerin infusion studies. In the analysis of these data, a t-test for paired variates was used to assess the significance of differences between P NE before and at maximal rates of infusion. Values of P Ͻ 0.05 were considered significant.
RESULTS
Baseline observations before AVP infusions. There were no significant differences in MAP, HR, or other hemodynamic parameters in quadriplegic subjects compared with normal subjects before the infusion of AVP, either before or after administration of the V 1 -receptor antagonist. In addition, administration of the V 1 -receptor antagonist in 0.9% NaCl (20 ml) before AVP infusions did not alter these parameters in either quadriplegic or normal subjects. These parameters in quadriplegic and normal subjects immediately before, during, and after AVP infusions are shown in Table 1 .
Hemodynamic effects of AVP infusions in the presence of V 1 -receptor antagonism. The effects of AVP infusion (400, 800, 1,600, and 3,200 U ⅐ kg Ϫ1 ⅐ min Ϫ1 in 10-min consecutive intervals) on MAP and HR in quadriplegic (n ϭ 7) and normal (n ϭ 5) subjects are shown in Fig. 1 . MAP in quadriplegic subjects decreased from preinfusion MAP to a nadir of 65 Ϯ 2 mmHg (P Ͻ 0.001) at the 800 U ⅐ kg Ϫ1 ⅐ min Ϫ1 AVP infusion rate and increased to 79 Ϯ 3 mmHg in the postinfusion period. HR progressively increased from 68 Ϯ 8 beats/ min before AVP infusion to 86 Ϯ 9 beats/min (P Ͻ 0.001) with increasing AVP infusion rates and remained higher than preinfusion HR (79 Ϯ 9 beats/min) in the postinfusion period. In contrast to the changes observed in the studies on quadriplegic subjects, MAP did not significantly change with increasing AVP infusion rates in normal subjects. However, HR progressively increased from 66 Ϯ 6 to 81 Ϯ 8 beats/min (P Ͻ 0.001).
CI progressively increased (P Ͻ 0.001), and SVRI decreased in both normal (P Ͻ 0.01) and quadriplegic (P Ͻ 0.001) subjects during incremental AVP infusion (Fig. 2) . LCWI, EF, EDI, and TFC were unchanged in ); EF, ejection fraction (%); EDI, end-diastolic index (ml/m 2 ); TFC, thoracic fluid conductivity (I/ohm); Pre, before; Post, after. * P Ͻ 0.05. quadriplegic subjects. Increases in LCWI (P Ͻ 0.001) and EF (P Ͻ 0.001) and a slight increase in EDI (P Ͻ 0.05) were noted in the studies in normal subjects, but there was no corresponding increase in TFC.
Hormonal changes during AVP infusions. The effects of AVP infusion on hormonal parameters in quadriplegic and normal subjects are shown in Table 2 . PRA increased from 1.7 Ϯ 0.4 to 5.6 Ϯ 1.2 ng ⅐ ml Ϫ1 ⅐ h Ϫ1 (P Ͻ 0.001) in quadriplegic subjects but did not change significantly in normal subjects. P NE concentrations progressively increased during AVP infusion in normal subjects (P Ͻ 0.001), whereas P NE increased in quadriplegic subjects only at the highest infusion rate. No effect of AVP infusion on P ANP and plasma cGMP concentrations was demonstrable.
Effects of nitroglycerin infusions in healthy control subjects. The effects of incremental nitroglycerin infusions on hemodynamic and hormonal parameters are shown in Tables 3 and 4 . MAP progressively decreased from 84 Ϯ 3 mmHg before infusion to a nadir of 69 Ϯ 5 mmHg (P Ͻ 0.001) at the maximal infusion rate. HR increased from 64 Ϯ 6 beats/min before nitroglycerin infusion to 73 Ϯ 9 beats/min (P Ͻ 0.001) at the maximal infusion rate. CI (P Ͻ 0.001), SI (P Ͻ 0.01), LCWI (P Ͻ 0.001), EDI (P Ͻ 0.001), and SVRI (P Ͻ 0.04) all decreased during incremental nitroglycerin infusions, whereas there were no significant changes in EF or TFC. P NE concentrations increased from 262 Ϯ 37 pg/ml before nitroglycerin infusion to 407 Ϯ 39 pg/ml (P Ͻ 0.001) at the maximal infusion rate. No effect of nitroglycerin infusions on PRA or plasma cGMP concentrations was demonstrable. P ANP concentrations did not significantly change during nitroglycerin infusion; however, there was marked between-subject variability in baseline P ANP concentrations.
DISCUSSION
Incremental infusions of AVP in the presence of V 1 -receptor blockade produced marked reductions in MAP in quadriplegic subjects but not in normal subjects. Maintenance of MAP at preinfusion levels in normal subjects, despite reductions in SVRI that were similar to those noted in quadriplegic subjects, can be attributed to increased CI due to the positive inotropic and chronotropic effects of baroreflex-mediated activation of the sympathetic nervous system and increased P NE concentrations. Such effects are evident in the increased SI, LCWI, and EF that were associated with the increase in CI in normal subjects. CI also increased in quadriplegic subjects but less so than in normal subjects. This increase in CI in quadriplegic subjects can be attributed mainly, if not entirely, to an increase in HR, which was presumably due to decreased parasympathetic inhibitory activity. In contrast to the changes in cardiac indexes in normal subjects, there were no changes in SI, LCWI, or EF during AVP infusions in quadriplegic subjects. There were no changes in EDI or TFC during AVP infusions in either quadriplegic or normal subjects. These observations show that AVP-induced vasodilation involving systemic resistance vessels can result in relatively large reductions in arterial pressure in the absence of a normal efferent sympathetic response. When sympathetic mechanisms affecting cardiac performance are Values are means Ϯ SE. PNE, plasma norepinephrine (pg/ml); PRA, plasma renin activity (ng ⅐ ml Ϫ1 ⅐ h Ϫ1 ); PANP, plasma atrial natriuretic peptide (pg/ml). * P Ͻ 0.05. intact, arterial pressure is maintained by an increase in CI and not by attenuation of the dilatory effect of AVP on systemic vascular resistance.
The reduction in arterial pressure in quadriplegic subjects was not prevented by stimulation of the reninangiotensin system as shown by the increase in PRA, which was negatively correlated with the reduction in MAP (R 2 ϭ 0.921, P Ͻ 0.01). Whether or not increased levels of ANG II may have played a role in the lack of reduction in EDI, TFC, and P ANP in quadriplegic subjects is uncertain. There were also no significant changes in plasma cyclic GMP concentrations, which is consistent with the absence of changes in P ANP in both quadriplegic and normal subjects. A close correlation between plasma cyclic GMP and atrial natriuretic peptide concentrations has been shown in previous studies (3, 12, 33) and reflects the direct effect of P ANP on particulate guanylate cyclase, an intermediate step in the production of cyclic GMP. Cyclic GMP is also generated by nitric oxide via a mechanism involving soluble guanylate cyclase, which has not been clearly associated with changes in plasma cyclic GMP concentrations (14, 23, 31) . Furthermore, plasma cyclic GMP concentrations in forearm venous blood did not increase during intra-arterial infusions of AVP, which produced vasodilation at high rates of infusion in studies reported by Suzuki et al. (31) . These investigators also found in forearm blood flow studies that plasma cyclic GMP concentrations did not change during intra-arterial infusions of sodium nitroprusside (31) .
The hemodynamic responses to nitroglycerin were substantially different from those observed in the AVP infusion studies in normal subjects, three of whom also participated in the nitroglycerin infusion studies. In the AVP infusion studies in normal subjects, HR, CI, SI, LCWI, and EF increased, SVRI decreased, and other measured parameters were unchanged. In contrast, during the nitroglycerin infusion studies, MAP, CI, SI, LCWI, and EDI all decreased, and reductions in SVRI were relatively small (Fig. 3) . There was an 18% decline in SVRI during vasopressin infusions, compared with a 2% decline in SVRI during nitroglycerin infusions. These responses to nitroglycerin infusions are consistent with a predominant vasodilatory effect on venous capacitance vessels, leading to a reduction in right atrial filling and to decreased CI and SI.
Variable hemodynamic effects of nitroglycerin have been reported, depending on route of administration (sublingual or intravenous), dosage, and cardiac status of study subjects. At low sublingual doses, dilation of systemic veins is the principal action of nitroglycerin (15, 22, 24, 29) . Any effect on peripheral arterioles is Values are means Ϯ SE. relatively small and is associated with little or no change in total systemic vascular resistance (22, 24) . Left ventricular end-diastolic pressure and volume are reduced (22, 24, 29) , and reductions in CI, SI, and systemic arterial pressure have been reported (37, 39) but are not consistently observed. In cardiac catheterization studies, Robin et al. (26) noted reductions in systolic arterial and left ventricular end-diastolic pressures and increases in HR, SI, and EF after 0.6-mg sublingual doses of nitroglycerin. CI was not significantly reduced in normal subjects but was reduced in patients with atherosclerotic heart disease. In studies reported by Christensson et al. (6) , intravenous nitroglycerin infusions at a rate lower than that used in our studies (0.17 mg/min) also decreased systolic arterial pressure and SI in supine normal subjects but with negligible effects on CI. Despite reductions in MAP and CI, there was no increase in PRA in our nitroglycerin infusion studies. However, few studies of the effect of nitroglycerin on renal vasculature have been reported. Vatner et al. (34) , in studies in conscious dogs, noted an early increase in renal blood flow associated with a reduction in renal vascular resistance during both intravenous and sublingual nitroglycerin administration. Dilation of renal vasculature after intra-arterial administration of nitroglycerin in dogs was reported by Frohlich et al. (8) . In studies of the central and regional hemodynamic effects of nitroglycerin in patients with congestive heart failure, Leier et al. (19) found that renal vascular resistance did not change and that renal blood flow decreased only slightly as systemic arterial pressure was reduced.
These studies show a clear differentiation of the hemodynamic effects of nitroglycerin from those associated with AVP-induced vasodilation after V 1 -receptor blockade. The primary vascular effect of AVP, which was unmasked by V 1 -receptor blockade, was a reduction in SVRI in both quadriplegic and normal subjects. The magnitude of reduction in SVRI was not affected by whether or not the sympathetic nervous system was intact. However, this did have an effect on the response of CI, which was twofold greater in normal subjects than in quadriplegic subjects. This increase in CI, due to reflex sympathetic stimulation in normal subjects, was sufficient to maintain systemic arterial pressure despite the reduction in SVRI. Whereas the relevance of these observations to normal cardiovascular homeostatic mechanisms is presently uncertain, this combination of primary and secondary hemodynamic responses may serve to maintain or increase peripheral blood flow in areas of the circulation where the vasodilatory effect of vasopressin is not normally countered by V 1 receptor-mediated vasoconstriction. Studies reported by Naitoh et al. (25) have suggested that vasodilation is the predominant effect of AVP on renal resistance vessels. Increases in renal blood flow produced by intravenous infusions of AVP in conscious dogs in these studies were further increased by prior administration of a V 1 -receptor antagonist and completely inhibited by administration of a V 2 -receptor antagonist. In studies showing biphasic changes in forearm vascular resistance during intra-arterial infusions of AVP, vasodilation produced by high rates of AVP infusion was augmented by L-arginine and inhibited by N G -monomethyl-L-arginine (L-NMMA), an inhibitor of nitric oxide generation by nitric oxide synthase, suggesting that the vasodilatory effect of AVP may be mediated by nitric oxide (32) . Although the hemodynamic responses to nitroglycerin, a known precursor of nitric oxide, were markedly different from those noted during AVP infusions in the presence of V 1 -receptor blockade in normal subjects, the possibility that nitric oxide might be involved in the vasodilatory effect of vasopressin is not excluded by these studies.
Perspectives
These studies provide further evidence that AVP may play a major role in complex homeostatic mechanisms that affect blood flow distribution through its vasodilatory as well as vasoconstrictive effects on resistance vessels. The vasodilatory effect, which is readily demonstrable after V 1 -receptor blockade in human subjects, is capable of inducing large changes in hemodynamic parameters and is closely associated with increasing plasma vasopressin concentrations. This latter association suggests that vasopressin may be involved in a mechanism that contributes to the preservation or enhancement of blood flow to organs or tissues that could be adversely affected by dehydration or volume depletion due to blood loss or other causes. The possibility that vasopressin-induced vasodilation may be mediated by V 2 or V 2 -equivalent receptors in blood vessels also suggests a unifying concept in which the antidiuretic action of vasopressin, which is known to be mediated by V 2 receptors on renal tubules, and its vasodilatory effect may function in concert to maintain essential blood flow during periods of actual or threatened volume deficiency.
